Procept BioRobotics wins FDA IDE for Aquablation prostate cancer therapy

The robotic technology used for the Aquablation procedure. [Image from the Procept BioRobotics website]Procept BioRobotics (Nasdaq:PRCT) announced today that it received FDA investigational device exemption (IDE) for its Aquablation therapy.

The IDE allows Procept to initiate a single-arm feasibility study for the Aquablation prostate cancer therapy in the U.S. Data generated from the study could support future research and regulatory applications in the U.S. The company plans to enroll patients with localized prostate cancer across three cancer centers in the country.

Redwood City, California-based Procept says the study takes place at Keck Medical Center (California), Perlmutter Cancer Center at NYU Langone Health and Mount Sinai Tisch Cancer Center (both New York).

About the Procept BioRobotics Aquablation therapy

Dr. Inderbir Gill, founding executive director for USC Urology as part of Keck, said Aquablation therapy provides efficacy and safety. Gill sa…

Read more
  • 0